Literature DB >> 9635923

Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units.

H Soda1, E Raymond, S Sharma, R Lawrence, C Cerna, L Gomez, G A Timony, D D Von Hoff, E Izbicka.   

Abstract

Bone morphogenetic protein-2 (BMP-2) is a differentiation factor for normal osteoblasts. BMP-2 is structurally related to transforming growth factor-beta which inhibits cell proliferation and enhances apoptosis. A recent study has shown the presence of BMP-2 receptors on several cancer cell lines. In this study, we attempted to determine if recombinant human BMP-2 (rhBMP-2) can modulate the proliferation of human tumor colony-forming units taken from 113 patients. Tumor cells were cultured in soft agar and continuously exposed to three concentrations of rhBMP-2 (10, 100 and 1000 ng/ml) for 14 days in the capillary cloning system. There were 65 evaluable specimens, including 17 breast cancers, 15 ovarian cancers, 14 non-small cell lung cancers and five prostate cancers. Importantly, rhBMP-2 did not stimulate the tumor cell proliferation. A significant inhibition (50% or less survival of tumor colony-forming units) was seen in 16 of 65 specimens (24.6%) at 1000 ng/ml, including five of 14 non-small cell lung cancers, five of 17 breast tumors and two of 15 ovarian tumors. A concentration-response relationship was observed (p<0.001 by Mantel-extension test). The results of this study encourage further evaluation of the antiproliferative effects of rhBMP-2 against human cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9635923     DOI: 10.1097/00001813-199804000-00006

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  13 in total

1.  Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.

Authors:  Philip Owens; Michael W Pickup; Sergey V Novitskiy; Anna Chytil; Agnieszka E Gorska; Mary E Aakre; James West; Harold L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

Review 2.  The Yin and Yang of bone morphogenetic proteins in cancer.

Authors:  Ashok Singh; Rebecca J Morris
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-04       Impact factor: 7.638

3.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Authors:  Z Deng; J H Morse; S L Slager; N Cuervo; K J Moore; G Venetos; S Kalachikov; E Cayanis; S G Fischer; R J Barst; S E Hodge; J A Knowles
Journal:  Am J Hum Genet       Date:  2000-07-20       Impact factor: 11.025

4.  Bone morphogenetic protein modulator BMPER is highly expressed in malignant tumors and controls invasive cell behavior.

Authors:  J Heinke; M Kerber; S Rahner; L Mnich; S Lassmann; T Helbing; M Werner; C Patterson; C Bode; M Moser
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

Review 5.  Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.

Authors:  Pawina Jiramongkolchai; Philip Owens; Charles C Hong
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

6.  Expression of bone morphogenetic protein-2 and its receptors in epithelial ovarian cancer and their influence on the prognosis of ovarian cancer patients.

Authors:  Ying Ma; Lin Ma; Quan Guo; Shulan Zhang
Journal:  J Exp Clin Cancer Res       Date:  2010-06-30

7.  Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth.

Authors:  Laura D Hover; Christian D Young; Neil E Bhola; Andrew J Wilson; Dineo Khabele; Charles C Hong; Harold L Moses; Philip Owens
Journal:  Cancer Lett       Date:  2015-07-30       Impact factor: 8.679

8.  Risk of Cancer Following Lumbar Fusion Surgery With Recombinant Human Bone Morphogenic Protein-2 (rhBMP-2): An Analysis Using a Commercially Insured Patient Population.

Authors:  Gregory S Cooper; Tzuyung Doug Kou
Journal:  Int J Spine Surg       Date:  2018-08-03

9.  Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures.

Authors:  Neil Ghodadra; Kern Singh
Journal:  Biologics       Date:  2008-09

10.  Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines.

Authors:  Elaine Langenfeld; Charles C Hong; Gandhi Lanke; John Langenfeld
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.